CAM
RXRX icon

Crown Advisors Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Crown Advisors Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-30,000
Closed -$319K – 50
2022
Q3 		$319K Buy
+30,000
New +$304K 0.32% 43

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Crown Advisors Management's RXRX Position: Q4 2022 in Review

Crown Advisors Management sold out of Recursion Pharmaceuticals (RXRX) in Q4 2022, closing a stake of 30,000 shares — an estimated $319K sold.

Crown Advisors Management first reported a position in RXRX in Q3 2022 and held it in 1 quarter. The position peaked at $319K in Q3 2022. 144 funds tracked by Wall St. Rank hold RXRX as of Q4 2022.

  • Crown Advisors Management reported no remaining Recursion Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Crown Advisors Management sold 30,000 Recursion Pharmaceuticals shares in Q4 2022, an estimated $319K.
  • Crown Advisors Management first reported a position in Recursion Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Crown Advisors Management's Recursion Pharmaceuticals position peaked at $319K in Q3 2022.
  • 144 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2022.

Based on Crown Advisors Management's 13F filing for Q4 2022, filed 9 Feb 2023.